Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases

M. Cosimelli, R. Golfieri, P. P. Cagol, L. Carpanese, R. Sciuto, C. L. Maini, R. Mancini, I. Sperduti, G. Pizzi, M. G. Diodoro, M. Perrone, E. Giampalma, B. Angelelli, F. Fiore, S. Lastoria, S. Bacchetti, D. Gasperini, O. Geatti, F. Izzo

Research output: Contribution to journalArticlepeer-review

Abstract

Background:This multi-centre phase II clinical trial is the first prospective evaluation of radioembolisation of patients with colorectal liver metastases (mCRC) who failed previous oxaliplatin-and irinotecan-based systemic chemotherapy regimens.Methods:Eligible patients had adequate hepatic, haemopoietic and renal function, and an absence of major hepatic vascular anomalies and hepato-pulmonary shunting. Gastroduodenal and right gastric arteries were embolised before hepatic arterial administration of yttrium-90 resin microspheres (median activity, 1.7 GBq; range, 0.9-2.2).Results:Of 50 eligible patients, 38 (76%) had received ≥4 lines of chemotherapy. Most presented with synchronous disease (72%),

Original languageEnglish
Pages (from-to)324-331
Number of pages8
JournalBritish Journal of Cancer
Volume103
Issue number3
DOIs
Publication statusPublished - Jul 27 2010

Keywords

  • chemorefractory
  • colorectal cancer
  • metastases
  • radioembolisation
  • selective internal radiation therapy
  • SIRT

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases'. Together they form a unique fingerprint.

Cite this